clinical trial · NCT04973566
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
Janssen Research & Development, LLC·phase1·completed·n = 48
HealthyNipocalimabEtanerceptHydroxychloroquine
brief summary
The primary purpose of this study is to assess the effect of nipocalimab on the pharmacokinetic (PK) of etanercept (Part 1); and to assess the effect of hydroxychloroquine (HCQ) on total serum immunoglobin G (IgG) reduction by nipocalimab (Part 2) in healthy participants.
started
Aug 31, 2021
primary completion
May 27, 2022
completion
May 27, 2022
last updated
Mar 4, 2025
official title
A Phase 1, Open-Label Study to Investigate Drug-Drug Interaction (DDI) Potential of Nipocalimab With Coadministration of Etanercept or Hydroxychloroquine in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol